The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...
Hosted on MSN
Vor Biopharma approves stock option repricing plan
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Vor Biopharma shares fell sharply Tuesday in premarket trading after the company priced its $100 million offering below recent trading prices. Shares traded 31% lower ahead of the morning bell at ...
Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share. The gross proceeds from the offering are expected to be $100 million. In ...
VOR Biopharma's valuation surged after in-licensing telitacicept and securing PIPE financing, but capital structure uncertainty persists. Telitacicept's positive phase 3 data in Sjögren's disease ...
Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.
We recently published These 10 Stocks are Winning Big. Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks on Monday. Vor Biopharma extended its winning streak to a fourth consecutive ...
Captain Vor is an iconic villain in Warframe and the first boss you’ll encounter in the game. Before the Isleweaver update, there were only two variants of Vor in the game: Captain Vor and Corrupted ...
Vor Bio grants CEO Jean-Paul Kress an option to purchase 83.3 million shares at $0.89, vesting over four years. Vor Bio, a biotechnology company specializing in autoimmune disease treatments, ...
Shares of Vor Bio VOR have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, the company entered a licensing agreement with RemeGen, a China-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results